Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity
about
Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in manDrug-induced liver injury: Advances in mechanistic understanding that will inform risk management.Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury.Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials.Mechanistic Modelling of Drug-Induced Liver Injury: Investigating the Role of Innate Immune Responses.The Promise of New Technologies to Reduce, Refine, or Replace Animal Use while Reducing Risks of Drug Induced Liver Injury in Pharmaceutical Development.Non-cytochrome P450-mediated bioactivation and its toxicological relevance.Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury.Are Polymorphisms in Genes Relevant to Drug Disposition Predictors of Susceptibility to Drug-Induced Liver Injury?Metabolomic approaches in the discovery of potential urinary biomarkers of drug-induced liver injury (DILI).Prediction of Altered Bile Acid Disposition Due to Inhibition of Multiple Transporters: An Integrated Approach Using Sandwich-Cultured Hepatocytes, Mechanistic Modeling, and Simulation.Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using Mechanistic in vitro Assays.Systems pharmacology modeling of drug-induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters.Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug-Induced Liver Injury.Inhibition of bile salt transport by drugs associated with liver injury in primary hepatocytes from human, monkey, dog, rat, and mouse.Quantitative Chemical Proteomic Profiling of the in Vivo Targets of Reactive Drug Metabolites.A Dynamic Mathematical Model of Bile Acid Clearance in HepaRG Cells.Exploring Chronic Drug Effects on Microengineered Human Liver Cultures Using Global Gene Expression Profiling.Biliary excretion of pravastatin and taurocholate in rats with bile salt export pump (Bsep) impairment.Can BSEP Inhibition Testing In Drug Discovery And Development Reduce Liver Injury Risk? - An International Transporter Consortium Perspective
P2860
Q28069617-55AF6B00-6BBB-45B9-BA77-44DBC8018A28Q30241050-8F2BF836-1543-4629-BFCA-DA82ED95D635Q34471194-99B169F9-F9EE-413D-B22E-DBD64F5A1718Q36972804-000FE734-499F-443F-A816-1E5B93D55273Q38374943-EE0C23C9-C5F2-4415-8745-86B103B3F651Q38725134-94A2424C-ED3F-466E-95C6-5977617B0651Q38774776-8F286D18-7855-4495-B3F1-8624E1417779Q38929936-7AE907E7-CF8E-4532-97DC-CB1F47F6DB01Q38958120-16445B14-B7A7-4A8D-98A7-5F6328425297Q39061191-D79D4079-B9A6-44EE-80A6-F220E69738E4Q39258217-32D972A2-5A9B-49A1-9C1F-F8B7900FDB71Q39730975-B198F982-D02D-43E3-9682-8C9C3C8F6C37Q40386706-D4EB4DD3-DA04-4C5C-845F-0D9EAF9A638EQ40701934-7E0846F1-0A9D-4081-B7F1-1A05EFE49B8BQ42091235-068C210A-9BCE-4948-BB63-9FE700AF8C0EQ43066578-95CCD430-FE62-448F-8C3E-E722B1F24660Q46576204-863FFF23-0F43-40FF-AFDC-9F16A756EF69Q46847239-23288D77-0509-4576-87F0-99151B9D3186Q47651234-5F5B0809-C65D-4BE8-8B0E-8F975170F915Q50755572-BD116943-2641-4EEA-8B7D-BECFC4D129D5Q53127205-E8B81562-4B80-4DBA-B92A-AFA664FB1DF8Q57111135-CF93C152-5612-45CF-A7B7-BDFB2F7C0AFA
P2860
Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Systems pharmacology modeling ...... ed troglitazone hepatotoxicity
@ast
Systems pharmacology modeling ...... ed troglitazone hepatotoxicity
@en
type
label
Systems pharmacology modeling ...... ed troglitazone hepatotoxicity
@ast
Systems pharmacology modeling ...... ed troglitazone hepatotoxicity
@en
prefLabel
Systems pharmacology modeling ...... ed troglitazone hepatotoxicity
@ast
Systems pharmacology modeling ...... ed troglitazone hepatotoxicity
@en
P2093
P2860
P356
P1476
Systems pharmacology modeling ...... ed troglitazone hepatotoxicity
@en
P2093
B A Howell
J L Woodhead
P B Watkins
P2860
P2888
P304
P356
10.1038/CLPT.2014.158
P407
P50
P577
2014-07-28T00:00:00Z
P5875
P6179
1052011650